Bank of New York Mellon Corp Has $1.53 Million Stock Position in SiBone (NASDAQ:SIBN)

Bank of New York Mellon Corp decreased its stake in SiBone (NASDAQ:SIBN) by 2.0% during the 1st quarter, HoldingsChannel reports. The fund owned 108,977 shares of the company’s stock after selling 2,229 shares during the period. Bank of New York Mellon Corp’s holdings in SiBone were worth $1,529,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of SiBone by 4.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company’s stock worth $328,000 after acquiring an additional 988 shares during the last quarter. Invesco Ltd. grew its stake in shares of SiBone by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company’s stock worth $241,000 after acquiring an additional 1,413 shares during the last quarter. Rhumbline Advisers grew its stake in shares of SiBone by 3.6% in the first quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock worth $838,000 after acquiring an additional 2,100 shares during the last quarter. Barclays PLC grew its stake in shares of SiBone by 2.7% in the fourth quarter. Barclays PLC now owns 99,212 shares of the company’s stock worth $1,391,000 after acquiring an additional 2,589 shares during the last quarter. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of SiBone in the fourth quarter worth $40,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analysts Set New Price Targets

SIBN has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of SiBone in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $24.00 target price on shares of SiBone in a research report on Tuesday, May 6th. Finally, Truist Financial raised their target price on SiBone from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th.

Insider Activity at SiBone

In other SiBone news, insider Anthony J. Recupero sold 4,147 shares of SiBone stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.56, for a total transaction of $81,115.32. Following the completion of the transaction, the insider directly owned 282,015 shares of the company’s stock, valued at approximately $5,516,213.40. This trade represents a 1.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey W. Dunn sold 3,377 shares of SiBone stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $19.05, for a total value of $64,331.85. Following the transaction, the director directly owned 17,354 shares of the company’s stock, valued at approximately $330,593.70. The trade was a 16.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 101,366 shares of company stock valued at $1,861,774. Insiders own 4.00% of the company’s stock.

SiBone Stock Down 0.1%

Shares of SIBN stock opened at $17.80 on Thursday. The stock has a market cap of $758.64 million, a P/E ratio of -27.81 and a beta of 0.93. SiBone has a one year low of $11.70 and a one year high of $20.05. The stock has a fifty day moving average price of $17.95 and a 200 day moving average price of $16.61. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.53 and a quick ratio of 7.26.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million during the quarter, compared to analysts’ expectations of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. Analysts predict that SiBone will post -0.78 earnings per share for the current year.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.